Outlook Therapeutics to Present at the Virtual Investor Roundtable Event
10. November 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual Conference
04. November 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina Showcases
03. November 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics’ Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic Bevacizumab
12. Oktober 2021 12:00 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting
07. Oktober 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
05. Oktober 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
28. September 2021 08:05 ET
|
Outlook Therapeutics, Inc.
Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of...
Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
21. September 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
13. September 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
08. September 2021 08:05 ET
|
Outlook Therapeutics, Inc.
ISELIN, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of...